| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenue | 479,533 | 444,328 | 621,401 | 647,145 |
| Cost of revenue | 379,759 | 343,943 | 540,708 | 540,302 |
| Selling, general and administrative expenses | 77,592 | 75,209 | 67,060 | 69,185 |
| Depreciation and amortization expenses | 23,615 | 23,141 | 29,701 | 29,870 |
| Loss (gain) on lease termination | 1,230 | 0 | - | - |
| Change in fair value of contingent consideration | -1,089 | 3,206 | 200 | - |
| Total operating expenses | 478,647 | 445,499 | 637,669 | 639,357 |
| Operating income (loss) | 886 | -1,171 | -16,268 | 7,788 |
| Interest income | 964 | 1,084 | 794 | 1,370 |
| Interest expense | 16,475 | 11,601 | 6,010 | 5,995 |
| Gain (loss) from equity method investees | 156 | 197 | -2,229 | -1,700 |
| Gain on extinguishment of short-term debt, net | 431 | - | - | - |
| Loss on option exercise | 0 | -196 | - | - |
| Extinguishment of series a preferred stock and other refinancing fees | 6,000 | 9,000 | - | - |
| Change in tax receivables agreement liability | 0 | 0 | - | - |
| Other expense, net | 80 | -35 | -43 | -105 |
| Loss before income taxes | -19,958 | -20,722 | -23,756 | 1,358 |
| Provision for (benefit from) income taxes | 906 | -825 | -619 | -238 |
| Loss before preferred dividends and accretion of series a preferred stock including excise tax | -20,864 | -19,897 | -23,137 | 1,596 |
| Dividends and accretion of series a preferred stock including excise tax | 6,066 | 31,193 | 8,094 | 7,979 |
| Net loss attributable to common shareholders of evolent health, inc. - diluted | -26,930 | -51,090 | -31,231 | -6,383 |
| Basic (in dollars per share) | -0.24 | -0.44 | -0.27 | -0.06 |
| Basic (in shares) | 114,066,000 | 115,882,000 | 114,862,000 | 114,688,000 |
| Diluted (in dollars per share) | -0.24 | -0.44 | -0.27 | -0.06 |
| Diluted (in shares) | 114,066,000 | 115,882,000 | 114,862,000 | 114,688,000 |
Evolent Health, Inc. (EVH)
Evolent Health, Inc. (EVH)